Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of “Buy” from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received a consensus rating of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $48.00.

A number of brokerages have recently issued reports on AAPG. Oppenheimer initiated coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Thursday. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Finally, Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter worth $391,000. Finally, Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at $610,000.

Ascentage Pharma Group International Stock Performance

AAPG stock opened at $22.96 on Monday. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The firm has a 50-day simple moving average of $24.01 and a 200-day simple moving average of $29.73.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.